|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net Sales | |||||
| Cost of products sold, excluding amortization of intangible assets | |||||
| Amortization of intangible assets | |||||
| Research and development | |||||
| Selling, general and administrative | |||||
| Total Operating Cost and Expenses | |||||
| Operating Earnings | |||||
| Interest expense | |||||
| Interest income | |||||
| Net foreign exchange (gain) loss | |||||
| Other (income) expense, net | |||||
| Earnings before Taxes | |||||
| Taxes on Earnings | |||||
| Net Earnings | |||||
| Basic Earnings Per Common Share (in dollars per share) | |||||
| Diluted Earnings Per Common Share (in dollars per share) | |||||
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | |||||
| Dilutive Common Stock Options (in shares) | |||||
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | |||||
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | |||||
Loading...